KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Acquisitions & Divestments: 2009-2024

Historic Change in Acquisitions & Divestments for Teva Pharmaceutical Industries (TEVA) over the last 13 years, with Sep 2024 value amounting to $40.0 million.

  • Teva Pharmaceutical Industries' Change in Acquisitions & Divestments was N/A to $40.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $63.0 million, marking a year-over-year change of. This contributed to the annual value of $40.0 million for FY2024, which is N/A change from last year.
  • As of Q3 2024, Teva Pharmaceutical Industries' Change in Acquisitions & Divestments stood at $40.0 million, which was up 3,900.00% from $1.0 million recorded in Q3 2022.
  • In the past 5 years, Teva Pharmaceutical Industries' Change in Acquisitions & Divestments registered a high of $107.0 million during Q2 2021, and its lowest value of $1.0 million during Q3 2022.
  • Moreover, its 2-year median value for Change in Acquisitions & Divestments was $3.0 million (2022), whereas its average is $14.7 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Change in Acquisitions & Divestments crashed by 97.56% in 2020 and then surged by 3,466.67% in 2021.
  • Over the past 4 years, Teva Pharmaceutical Industries' Change in Acquisitions & Divestments (Quarterly) stood at $3.0 million in 2020, then soared by 533.33% to $19.0 million in 2021, then tumbled by 94.74% to $1.0 million in 2022, then reached $40.0 million in 2024.
  • Its last three reported values are $40.0 million in Q3 2024, $1.0 million for Q3 2022, and $3.0 million during Q2 2022.